Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,930,120.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $518.96, for a total value of $4,930,120.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at $168,372,939.28. The trade was a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Up 0.1%

UTHR stock opened at $519.34 on Thursday. The firm has a market cap of $22.05 billion, a PE ratio of 19.17, a P/E/G ratio of 1.73 and a beta of 0.59. The business has a 50 day moving average of $540.37 and a 200-day moving average of $533.71. United Therapeutics Corporation has a 12-month low of $292.34 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the company posted $6.41 earnings per share. United Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, research analysts expect that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Leuthold Group LLC boosted its stake in United Therapeutics by 41.4% during the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after buying an additional 3,126 shares during the period. UBS Group AG increased its stake in United Therapeutics by 45.3% in the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after acquiring an additional 70,445 shares during the last quarter. Perpetual Ltd bought a new position in United Therapeutics in the 4th quarter worth about $1,059,000. Nicholas Investment Partners LP raised its holdings in shares of United Therapeutics by 478.5% in the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after acquiring an additional 3,766 shares in the last quarter. Finally, LBP AM SA purchased a new position in shares of United Therapeutics during the fourth quarter worth about $9,745,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics reported second-quarter adjusted earnings of $7.27 per share, exceeding analyst estimates of roughly $6.82–$6.86 and rising from $6.41 a year earlier. Net income also increased, signaling stronger profitability despite softer sales. United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management highlighted the submission of two new drug applications, including ralinepag for rare pulmonary disease. Regulatory progress could expand the company’s pipeline and provide longer-term growth beyond its existing pulmonary arterial hypertension franchise. United Therapeutics Q2 Net Income Rises, Revenue Falls
• Neutral Sentiment: The earnings call and presentation gave investors additional detail on quarterly performance, pipeline development and upcoming regulatory milestones. Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $648, above recent trading levels. United Therapeutics Corporation Q2 2026 Earnings Call Transcript
• Negative Sentiment: Second-quarter revenue declined approximately 2% year over year to $783.3 million, compared with $798.6 million a year earlier. The sales decline suggests that earnings growth was driven more by profitability and cost dynamics than by accelerating top-line demand. United Therapeutics Reports Q2 Earnings: Key Metrics
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares worth about $4.9 million, reducing her direct ownership by 2.84%. While the sale may be routine, insider selling can create a modest overhang for investor sentiment. United Therapeutics CEO SEC Filing

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, July 31st. Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $648.33.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.